Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, With 1 to 3 Positive Nodes: A Single-Centre Study

Background: There is a tendency to decrease the intensity of breast cancer treatments, e.g. omitting adjuvant chemotherapy in endocrine-sensitive and HER-2 negative patients. The purpose of this study was to analyse changes in the frequency of the indication of adjuvant chemotherapy and the differe...

Full description

Bibliographic Details
Main Authors: José Manuel Baena Cañada, Carlos de la Torre Hita, Marta Bernal Gómez, Alicia Campini Bermejo, Salvador Gámez Casado, Lourdes Rodríguez Pérez, Alicia Quílez Cutillas, Julio Calvete Candenas, Sara Estalella Mendoza, Encarnación Benítez Rodríguez
Format: Article
Language:English
Published: Kaviani Breast Disease Institute 2021-07-01
Series:Archives of Breast Cancer
Subjects:
Online Access:https://www.archbreastcancer.com/index.php/abc/article/view/409
id doaj-02b41ead8e914ccfb281281d854ff377
record_format Article
spelling doaj-02b41ead8e914ccfb281281d854ff3772021-07-28T08:53:39ZengKaviani Breast Disease InstituteArchives of Breast Cancer2383-04332021-07-0110.32768/abc.202183233-242Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, With 1 to 3 Positive Nodes: A Single-Centre StudyJosé Manuel Baena Cañada0Carlos de la Torre Hita1Marta Bernal Gómez2Alicia Campini Bermejo3Salvador Gámez Casado4Lourdes Rodríguez Pérez5Alicia Quílez Cutillas6Julio Calvete Candenas7Sara Estalella Mendoza8Encarnación Benítez Rodríguez9Medical Oncology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain b Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), SpainMedical Oncology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain AND Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), SpainMedical Oncology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain AND Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), SpainMedical Oncology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain AND Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), SpainMedical Oncology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain AND Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), SpainMedical Oncology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain AND Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), SpainMedical Oncology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain AND Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), SpainMedical Oncology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain AND Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), SpainMedical Oncology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain AND Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), SpainInstituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Spain AND Provincial Cancer Register, Regional Health Authority, Cádiz, Spain Background: There is a tendency to decrease the intensity of breast cancer treatments, e.g. omitting adjuvant chemotherapy in endocrine-sensitive and HER-2 negative patients. The purpose of this study was to analyse changes in the frequency of the indication of adjuvant chemotherapy and the differences in survival over time for this subtype of breast cancer, with 1–3 positive nodes. Methods: The study was based on descriptive, observational, retrospective, single-institution research between 2004–10 and 2011–18, on endocrine-sensitive, HER-2 negative breast cancer, stage pN1 (1–3 nodes). The analytical tests carried out for a comparison of the frequency of chemotherapy use the chi-square test with Fisher's exact test. Survival data in both periods are presented. Results: A total of 236 patients were included, 66 for the period 2004–10, and 170 for 2011–18. More patients were treated with hormone therapy alone in 2011–18: hormone therapy alone 10/66 (15.20%) for 2004–10, and 83/169 (49.10%) for 2011–18; chemotherapy-hormone therapy 56/66 (84.80%) for 2004–10, and 86/169 (50.90%) for 2011–18 (P = 0.0001). For 2004–10, the 5-year overall survival probability was 100%. For 2011–18 it was 98.20% (95% CI 95.65–100). For 2004-10, 5-year disease free survival (DFS) was 96.9% (95% CI 92.7–101). For 2011–18 it was 87.7% (95% CI 81.8–93.5) (P=0,040). For 2004–10 the 5 year distant relapse free interval was 96.9% (95% CI 92.5–101.2). For 2011–18 it was 93% (95% CI 88.1–97.9) (P=0.312). Conclusion: A decrease in the indication of adjuvant chemotherapy according to the clinical risk is confirmed in endocrine-sensitive, HER-2 negative breast cancer, with 1-3 positive nodes, over the period 2011–18 compared to 2004–10. Based on the results, 5-year DFS is slightly worse in the 2011–18 period. https://www.archbreastcancer.com/index.php/abc/article/view/409Breast neoplasmHormonal Antineoplastic AgentsAdjuvant ChemotherapySurvivalSystemic adjuvant therapies
collection DOAJ
language English
format Article
sources DOAJ
author José Manuel Baena Cañada
Carlos de la Torre Hita
Marta Bernal Gómez
Alicia Campini Bermejo
Salvador Gámez Casado
Lourdes Rodríguez Pérez
Alicia Quílez Cutillas
Julio Calvete Candenas
Sara Estalella Mendoza
Encarnación Benítez Rodríguez
spellingShingle José Manuel Baena Cañada
Carlos de la Torre Hita
Marta Bernal Gómez
Alicia Campini Bermejo
Salvador Gámez Casado
Lourdes Rodríguez Pérez
Alicia Quílez Cutillas
Julio Calvete Candenas
Sara Estalella Mendoza
Encarnación Benítez Rodríguez
Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, With 1 to 3 Positive Nodes: A Single-Centre Study
Archives of Breast Cancer
Breast neoplasm
Hormonal Antineoplastic Agents
Adjuvant Chemotherapy
Survival
Systemic adjuvant therapies
author_facet José Manuel Baena Cañada
Carlos de la Torre Hita
Marta Bernal Gómez
Alicia Campini Bermejo
Salvador Gámez Casado
Lourdes Rodríguez Pérez
Alicia Quílez Cutillas
Julio Calvete Candenas
Sara Estalella Mendoza
Encarnación Benítez Rodríguez
author_sort José Manuel Baena Cañada
title Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, With 1 to 3 Positive Nodes: A Single-Centre Study
title_short Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, With 1 to 3 Positive Nodes: A Single-Centre Study
title_full Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, With 1 to 3 Positive Nodes: A Single-Centre Study
title_fullStr Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, With 1 to 3 Positive Nodes: A Single-Centre Study
title_full_unstemmed Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, With 1 to 3 Positive Nodes: A Single-Centre Study
title_sort trends in adjuvant chemotherapy use in endocrine-sensitive, her-2 negative breast cancer, with 1 to 3 positive nodes: a single-centre study
publisher Kaviani Breast Disease Institute
series Archives of Breast Cancer
issn 2383-0433
publishDate 2021-07-01
description Background: There is a tendency to decrease the intensity of breast cancer treatments, e.g. omitting adjuvant chemotherapy in endocrine-sensitive and HER-2 negative patients. The purpose of this study was to analyse changes in the frequency of the indication of adjuvant chemotherapy and the differences in survival over time for this subtype of breast cancer, with 1–3 positive nodes. Methods: The study was based on descriptive, observational, retrospective, single-institution research between 2004–10 and 2011–18, on endocrine-sensitive, HER-2 negative breast cancer, stage pN1 (1–3 nodes). The analytical tests carried out for a comparison of the frequency of chemotherapy use the chi-square test with Fisher's exact test. Survival data in both periods are presented. Results: A total of 236 patients were included, 66 for the period 2004–10, and 170 for 2011–18. More patients were treated with hormone therapy alone in 2011–18: hormone therapy alone 10/66 (15.20%) for 2004–10, and 83/169 (49.10%) for 2011–18; chemotherapy-hormone therapy 56/66 (84.80%) for 2004–10, and 86/169 (50.90%) for 2011–18 (P = 0.0001). For 2004–10, the 5-year overall survival probability was 100%. For 2011–18 it was 98.20% (95% CI 95.65–100). For 2004-10, 5-year disease free survival (DFS) was 96.9% (95% CI 92.7–101). For 2011–18 it was 87.7% (95% CI 81.8–93.5) (P=0,040). For 2004–10 the 5 year distant relapse free interval was 96.9% (95% CI 92.5–101.2). For 2011–18 it was 93% (95% CI 88.1–97.9) (P=0.312). Conclusion: A decrease in the indication of adjuvant chemotherapy according to the clinical risk is confirmed in endocrine-sensitive, HER-2 negative breast cancer, with 1-3 positive nodes, over the period 2011–18 compared to 2004–10. Based on the results, 5-year DFS is slightly worse in the 2011–18 period.
topic Breast neoplasm
Hormonal Antineoplastic Agents
Adjuvant Chemotherapy
Survival
Systemic adjuvant therapies
url https://www.archbreastcancer.com/index.php/abc/article/view/409
work_keys_str_mv AT josemanuelbaenacanada trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
AT carlosdelatorrehita trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
AT martabernalgomez trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
AT aliciacampinibermejo trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
AT salvadorgamezcasado trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
AT lourdesrodriguezperez trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
AT aliciaquilezcutillas trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
AT juliocalvetecandenas trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
AT saraestalellamendoza trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
AT encarnacionbenitezrodriguez trendsinadjuvantchemotherapyuseinendocrinesensitiveher2negativebreastcancerwith1to3positivenodesasinglecentrestudy
_version_ 1721278864603217920